Paper42432811
iPSC-Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice.
Zhang M and 14 others. Cell Prolif, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. iPSC-Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice. Papers, record 42432811. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42432811
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- iPSC-Derived iNK Progenitors Engraft and Generate NK Cells in Unconditioned and Autologous Immune Humanized Mice.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 82450001 | the National Natural Science Foundation of China | PubMed | ||
| 82300132 | the National Natural Science Foundation of China | PubMed | ||
| 32300676 | the National Natural Science Foundation of China | PubMed | ||
| 82470120 | the National Natural Science Foundation of China | PubMed | ||
| 2024YFA1108302 | the National Key R&D Program of China | PubMed | ||
| 2023ZD0501200 | the Noncommunicable Chronic Diseases-National Science and Technology Major Project | PubMed |
Source PubMed
References18
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36344493 | Lateral plate mesoderm cell-based organoid system for NK cell regeneration from human pluripotent stem cells. | Cell Discov | 2022 | https://conductscience.org/library/papers/36344493 | PubMed |
| 2 | 16904174 | Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. | Cell | 2006 | https://conductscience.org/library/papers/16904174 | PubMed |
| 3 | 23302801 | Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. | Nature | 2013 | https://conductscience.org/library/papers/23302801 | PubMed |
| 4 | 23352605 | Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. | Cell Stem Cell | 2013 | https://conductscience.org/library/papers/23352605 | PubMed |
| 5 | 34794791 | Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia. | Hematol Transfus Cell Ther | 2021 | https://conductscience.org/library/papers/34794791 | PubMed |
| 6 | 38819365 | Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors. | Cytotherapy | 2024 | https://conductscience.org/library/papers/38819365 | PubMed |
| 7 | 18035408 | Induction of pluripotent stem cells from adult human fibroblasts by defined factors. | Cell | 2007 | https://conductscience.org/library/papers/18035408 | PubMed |
| 8 | 40251398 | Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial. | Nat Cancer | 2025 | https://conductscience.org/library/papers/40251398 | PubMed |
| 9 | 39664387 | Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals. | Front Immunol | 2024 | https://conductscience.org/library/papers/39664387 | PubMed |
| 10 | 38926847 | Adoptive NK cell therapy: a potential revolutionary approach in longevity therapeutics. | Immun Ageing | 2024 | https://conductscience.org/library/papers/38926847 | PubMed |
| 11 | 41135520 | Engineered natural killer cells for cancer therapy. | Cancer Cell | 2025 | https://conductscience.org/library/papers/41135520 | PubMed |
| 12 | 37291236 | Expanded clinical-grade NK cells exhibit stronger effects than primary NK cells against HCMV infection. | Cell Mol Immunol | 2023 | https://conductscience.org/library/papers/37291236 | PubMed |
| 13 | 37481703 | Efficient T cell adoptive transfer in lymphoreplete hosts mediated by transient activation of Stat5 signaling. | Mol Ther | 2023 | https://conductscience.org/library/papers/37481703 | PubMed |
| 14 | 17346281 | In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. | Immunology | 2007 | https://conductscience.org/library/papers/17346281 | PubMed |
| 15 | 40148484 | Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma. | Bone Marrow Transplant | 2025 | https://conductscience.org/library/papers/40148484 | PubMed |
| 16 | 21572395 | Immunogenicity of induced pluripotent stem cells. | Nature | 2011 | https://conductscience.org/library/papers/21572395 | PubMed |
| 17 | 41742420 | Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models. | Cell Stem Cell | 2026 | https://conductscience.org/library/papers/41742420 | PubMed |
| 18 | 18029452 | Induced pluripotent stem cell lines derived from human somatic cells. | Science | 2007 | https://conductscience.org/library/papers/18029452 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42432811
GET https://conductscience.org/api/papers/v1/42432811/authors